Clinical Trials News

SAN DIEGO--(BUSINESS WIRE)--Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program...

DUBLIN--(BUSINESS WIRE)--The "CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Highlights: First CD137 Targeted Therapy Commercial Launch Expected by 2030 Insight on CD137 Targeted Therapies in Clinical Trials: > 90 Therapies CD137 Targeted Therapies Clinical Trials Insight by Company, Country, Indication and Phase Highest Clinical Trials P...

DUBLIN--(BUSINESS WIRE)--The "MYC Targeting Therapies Market Opportunity, Targeting Approaches, Technology Development Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: First MYC Targeting Therapy Approval Expected by 2030 Global MYC Targeting Therapies Market Opportunity Outlook Comprehensive Insight on MYC Targeting Therapies in Clinical Trials: > 10 Therapies MYC Targeting Drugs Clinical Trials Insig...

MORGES, Switzerland--(BUSINESS WIRE)--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.2 Howeve...

LAS VEGAS--(BUSINESS WIRE)--Gilad&Gilad launches AgmaVet® For Horses containing the neuroprotective ingredient G-Agmatine® for resilient nerve functions and joints mobility....

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy comme...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T). In the NEAT study, the company’s pivotal Phase 3 in...

BEDMINSTER, N.J.--(BUSINESS WIRE)--In a supplement category long dominated by stimulants, appetite suppressants and short-term fixes, Biocodex is introducing a fundamentally different approach. The science-driven health & wellness company behind Florastor® recently announced the U.S. launch of Fullify™, a first-of-its-kind precision probiotic developed to support appetite management and weight loss by working with the body’s natural gut-brain signaling. Developed in France and now available...